Director/PDMR Shareholding
Director/PDMR Shareholding
The transaction involves the gift of 255,440 Ordinary Shares to
Following completion of this transfer,
The information contained in this notification is disclosed in accordance with the requirements of the EU Market Abuse Regulation as it forms part of
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
a) |
|
|
|
2 |
Reason for the notification |
||
a) |
Position/status |
Chief Executive Officer |
|
b) |
Initial notification /Amendment |
Initial Notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
a) |
|
|
|
b) |
Legal Entity Identifier |
213800NTOH3FK3WER551 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of
ISIN Code: GB00BYWL4Y04 |
|
b) |
Nature of the transaction |
Gift of shares to a trust for nil consideration Sale of shares to a trust
|
|
c) |
Currency |
N/A |
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
Nil |
255,440 Ordinary Shares |
||
|
|
|
2,298,958 Ordinary Shares |
|
|
|
|
e) |
Aggregated information - Aggregated volume - Price - Aggregated total
- Aggregated volume - Price - Aggregated total |
255,440 Nil Nil
2,298,958
|
|
f) |
Date of the transaction |
|
|
g) |
Place of the transaction |
Outside a trading venue |
For further information, please contact:
|
||
|
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker ) |
Tel: 020 7710 7600 |
|
|
|
|
|
|
|
|
Tel: 020 7597 4000 |
|
|
|
|
|
|
|
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
|
Mob: 07980 541 893 / 07584 391 303 |
|
|
|
|
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The
* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the